Objective-Angiopoietin-like protein 2 (ANGPTL2), a proinflammatory mediator, has been reported to accelerate the development of insulin resistance, endothelial dysfunction, and atherosclerosis in mice. However, no cohort studies have examined the relationship between serum ANGPTL2 levels and the development of cardiovascular disease (CVD) in a general population. Approach and Results-A total of 3005 community-dwelling Japanese aged ≥40 years without a history of CVD were divided into 4 groups according to the quartiles of serum ANGPTL2 concentrations (Q1, lowest and Q4, highest) and followed up for 10 years. The hazards ratios and their 95% confidence intervals for the development of CVD (coronary heart disease or stroke) were estimated using a Cox proportional hazards model. During the follow-up, 219 first-ever CVD events were observed. 
A ngiopoietin-like protein 2 (ANGPTL2) is a member of a protein family whose members are structurally similar to angiopoietins. 1, 2 It has been reported that ANGPTL2 is a proinflammatory mediator, and it accelerates the development of insulin resistance, endothelial dysfunction, and atherosclerosis in mice. [2] [3] [4] [5] Histological studies of mice and humans have shown that ANGPTL2 is abundantly expressed in visceral adipose tissue, endothelial cells, and macrophages infiltrating atheromatous plaques. [2] [3] [4] [5] In healthy volunteers, an elevated concentration of serum ANGPTL2 was closely associated with obesity, insulin resistance, and increased levels of serum high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker. 3 Because these conditions are well known to be risk factors for the development of cardiovascular disease (CVD), [6] [7] [8] [9] [10] [11] [12] we hypothesized that increased concentrations of serum ANGPTL2 might be involved in the development of CVD through the accumulation of metabolic disorders and inflammation. However, no prospective epidemiological studies have examined the possible association between serum ANGPTL2 levels and the development of CVD or the possible roles of metabolic disorders and inflammation as mediators in such an association.
The aim of this study was to investigate these issues in a cohort study of a general population, with consideration for comprehensive cardiovascular risk factors including components of metabolic syndrome and serum levels of hs-CRP.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
The baseline characteristics of the study population according to the quartiles of serum ANGPTL2 concentrations are shown in Table 1 . The mean values of age, waist circumference, body mass index, systolic and diastolic blood pressures, fasting plasma glucose, and serum levels of low-density lipoprotein cholesterol, triglycerides, and hs-CRP increased significantly with elevating serum ANGPTL2 levels. The subjects with higher serum ANGPTL2 levels had significantly higher frequencies of antihypertensive medication, antidiabetic medication, lipid-lowering medication, ECG abnormalities, regular exercise, metabolic syndrome, and its components. In contrast, the mean values of serum high-density lipoprotein cholesterol and frequencies of current smoking and drinking decreased significantly with higher serum ANGPTL2 levels. Serum ANGPTL2 levels did not show a clear association with sex and total cholesterol levels. Figure I in the online-only Data Supplement shows the distributions of baseline serum ANGPTL2 concentrations in subjects with and without CVD events during the follow-up. The distribution of serum ANGPTL2 in subjects with CVD was significantly higher than in those without CVD (P<0.001). Values are means (SD), percentages, or medians (interquartile ranges). ANGPTL2 indicates angiopoietin-like protein 2; HDL, high-density lipoprotein; hs-CRP, highsensitivity C-reactive protein; and LDL, low-density lipoprotein.
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Figure demonstrates the age-and sex-adjusted incidence rates of CVD and its subtypes according to the serum ANGPTL2 levels. The incidence rates of total CVD and coronary heart disease increased significantly with elevating serum ANGPTL2 levels (P for trend=0.005 and 0.01, respectively). A similar but nonsignificant trend was observed for the incidence rate of stroke (P for trend=0.07). Table 2 and Figure II in the online-only Data Supplement show the hazard ratios (HRs) for the development of CVD and its subtypes according to the serum ANGPTL2 levels. In model 1 with adjustment for age and sex, higher serum ANGPTL2 levels were significantly associated with an increased risk of total CVD (P for trend=0.005). This association remained significant after adjustment for conventional cardiovascular risk factors other than metabolic syndrome components (model 2, P for trend=0.003), and even after additional adjustment for metabolic syndrome components (model 3, P for trend=0.006) and serum hs-CRP (model 4, P for trend=0.02). A similar association was observed for coronary heart disease and stroke analyzed separately, although the associations with coronary heart disease in model 4 and with stroke in model 1 and model 4 did not reach the level of statistical significance. Table 3 summarizes the HRs for the development of total CVD per 1 SD increment in log-transformed serum ANGPTL2 concentrations. In model 2, elevated ANGPTL2 was significantly associated with a higher risk of total CVD (HR, 1.19; 95% confidence interval, 1.03-1.38). The association diminished slightly when metabolic syndrome components were added into model 2 as a reference model (HR, 1.18; 95% confidence interval, 1.02-1.37; % reduction in log HR, 4.8%). The association attenuated moderately when serum hs-CRP was added into model 2 (HR, 1.15; 95% confidence interval, 0.99-1.33; % reduction in log HR, 22.0%) or when both metabolic syndrome components and serum hs-CRP were added into model 2 (HR, 1.14; 95% confidence interval, 0.98-1.34; % reduction in log HR, 22.7%).
Discussion
In this study, we demonstrated that the risk for the development of CVD increased significantly and linearly with elevating serum ANGPTL2 levels even after adjustment for conventional cardiovascular risk factors other than metabolic syndrome components. This association diminished but remained significant after additional adjustment for metabolic syndrome components and serum hs-CRP levels. These findings suggest that elevated serum ANGPTL2 levels are a novel risk factor for CVD, and the association is partially mediated by metabolic disorders and inflammation.
Some cross-sectional and case-control studies have shown the positive associations between serum ANGPTL2 levels and the presence of CVD and its surrogate outcomes, such as acute coronary syndrome, 13 heart failure, 14 carotid atherosclerosis, 15 and albuminuria. 16 In our recent cross-sectional and prospective cohort surveys of the Hisayama Study, elevated serum ANGPTL2 levels were significantly associated with a higher prevalence of chronic kidney disease 17 and an increased risk for the development of type 2 diabetes mellitus. 18 However, the longitudinal association of serum ANGPTL2 levels with the development of CVD in general populations remained unclear. To the best of our knowledge, this study is the first prospective cohort study to demonstrate that elevated serum ANGPTL2 concentrations were a significant risk factor for the development of CVD in the general population.
Several biological mechanisms could potentially explain the positive association between serum ANGPTL2 levels and the risk of CVD. ANGPTL2 is an adipokine secreted from adipose tissues, 3 and it has been reported that serum ANGPTL2 concentrations were elevated in metabolic syndrome in mouse models and humans, 3, 19 suggesting that elevated serum ANGPTL2 concentrations may be a marker for the presence of metabolic syndrome. The latter, which is a clustering of metabolic disorders including abdominal obesity, dyslipidemia, hyperglycemia, and elevated blood pressure, has been recognized as one of the established risk factors for CVD. 20, 21 Thus, the association between serum ANGPTL2 levels and the future development of CVD might be attributable to the presence of metabolic syndrome. Experimental studies have shown that ANGPTL2 works as a proinflammatory mediator. [2] [3] [4] [5] Adipocyte-derived ANGPTL2 is reported to be a key mediator linking obesity to adipose tissue inflammation. An animal study showed that ANGPTL2 in adipose tissue induces chronic adipose tissue inflammation and systemic insulin resistance, 2,3 resulting in an increased CVD risk. In addition, endothelium-derived ANGPTL2 promotes vascular inflammation, most likely via the integrin α5β1/Rac1/NF-κB (nuclear factor-kappa B) pathway. 2 Because vascular injury accompanied by inflammation is considered to be an early feature of atherosclerosis, serum ANGPTL2 may be involved in the initiation and progression of atherosclerosis, resulting in an elevated risk of CVD. These facts suggest that the association between serum ANGPTL2 levels and the risk of CVD could be explained by the presence of ANGPTL2-induced inflammation in adipose tissue and arteries. In this study, the ANGPTL2 indicates angiopoietin-like protein 2; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular disease; and HR, hazard ratios. *Model 1: adjusted for age and sex. †Model 2: adjusted for the covariates in model 1+total cholesterol, lipid-lowering medication, ECG abnormalities, smoking habits, alcohol intake, and regular exercise. ‡Model 3: adjusted for the covariates in model 2+metabolic syndrome components (elevated waist circumference, high blood pressure, high fasting plasma glucose, low high-density lipoprotein cholesterol, and high triglycerides). §Model 4: adjusted for the covariates in model 3+high-sensitivity C-reactive protein. magnitude of the association of serum ANGPTL2 levels with the CVD risk was attenuated by 4.8% after adjustment for metabolic syndrome components and by 22.0% after adjustment for serum hs-CRP levels, indicating that the association can be partially explained by metabolic disorders and inflammation. Nevertheless, the association between ANGPTL2 quartiles and the CVD risk remained significant in the fully adjusted model, including metabolic syndrome components and serum hs-CRP levels (Table 2 , model 4), suggesting that mechanisms other than metabolic disorders and inflammation may exist. However, although we controlled for a wide range of confounding factors in this analysis, the possibility of residual confounders may exist. In particular, serum hs-CRP levels may not entirely explain inflammation status because inflammation involves complex processes reflected in a variety of surrogate markers other than hs-CRP. ANGPTL2 is not the only determinant of hs-CRP; other inflammatory mediators, such as interleukins and tumor necrosis factors, are also wellknown determinants of hs-CRP. Therefore, the influence of ANGPTL2-induced inflammation might not be fully adjusted by adding hs-CRP in model 4. Further investigations will be required to elucidate other possible mechanisms underlying the association between serum ANGPTL2 levels and CVD. This study had several important merits, namely, the community-based prospective design, high participation rate in the baseline examination, and complete follow-up survey. 22 However, some limitations should also be noted. First, ANGPTL2 concentrations were determined using serum samples frozen in long-term storage. Long-term storage time might result in the degradation of ANGPTL2 protein and possibly an exponential decrease in the concentrations of ANGPTL2 protein. However, because such a decrease in concentration was likely to occur equally among the samples, the possibility of misclassification in the ANGPTL2 quartiles may have been small and may have only minimally influenced the association observed in this study. Second, our findings were based on a single measurement of serum ANGPTL2 concentrations at baseline. The variability of serum ANGPTL2 concentrations during the follow-up was not taken into consideration. This limitation might weaken the association observed in this study, biasing the results toward the null hypothesis. Thus, the true association might be stronger than that observed. Finally, it remains unclear whether the conclusions of this study can be generalized to other ethnic populations with different genetic and lifestyle backgrounds because the prevalence of obesity and serum concentrations of hs-CRP are lower in Japanese than in Western people. 23 In conclusion, the findings of this study suggest that elevated serum concentrations of ANGPTL2 are a novel risk factor for the development of CVD, and that this association is partially mediated by metabolic disorders and inflammation. Further experimental, epidemiological, and clinical studies will be needed to reveal the precise role of ANGPTL2 in the development of CVD.
